| Technology Licensing |
|
Technology licensing for medical products has gained the momentum between China and western countries in the past years, and is believed to grow in next decades due to the strong demand for technologically advanced products by the local market. In addition, the strong drive by oversea returnees and increased investment in high tech industries by private sectors and the government also propel the advancement in technology innovation and scientific discovery in China. The key for the across border technology licensing is to structure the applicable deal term that meet the business interest of both parties.
Our consultants have strong technology backgrounds in multiple disciplines including investment analysis, biotechnology, API synthesis, pharmaceutical development and formulation technology. These expertise can be invaluable to our clients in conducting due diligence analysis and developing the terms that can meet the business objectives of interested parties.
Our technology licensing service includes:
Testimonial“The folks at China Healthcare Group have represented AcryMed's interests well in both China and South Korea. Their understanding of the cultures and their excellent attention to partnership introductions and negotiations of licensing agreements have landed us perfect partnerships in both of these markets. CHG continued function as a facilitator was essential in translating paper agreements into working relationships and true business for us. We are very proud of our Asian partners and delighted with our several years relationship with CGH which we expect will further assist us in tapping new market opportunities."—Bruce Gibbins, the Chief Technology Officer, AcryMed,Inc., the United States. |
| Next > |
|---|
Service Activities
Industrial News
- China Aoxing Pharmaceutical Company Receives Government Approval for Increased Ownership of its Main
- Reform to target hefty medicine costs
- China to develop traditional medicine vigorously
- Novartis to move Indian R&D operations to China: Financial Times
- India and China competing on pharma potential